Psychedelics

Our Newest Investment is Emyria (ASX: EMD)

Next Investors Sep 04, 2023

Today we announce our latest Investment, Emyria (ASX: EMD). Today we will outline what EMD does and how the company makes money.

Market responding well to Psychedelics for mental health progress

Next Investors Aug 17, 2021

CPH yesterday went on to announce the successful grant of a rare “Controlled Drugs and Substances license” licence for Haluenex in Canada, another positive step in their psychedelics story.

What We DO and DON’T like about the proposed CPH Merger

Next Investors Jun 17, 2021

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

CPH to expand US footprint after USOTC listing

Finfeed Archived Jun 11, 2021

The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.

Creso’s acquisition target Halucenex to extend clinical trials beyond veterans

Finfeed Archived Jun 08, 2021

Creso Pharma's (ASX: CPH) targeted acquisition company Halucenex intends to expand its phase II clinical trial to include non-veterans.

Bill passed: wide range of psychedelics could be made legal in the US

Finfeed Archived Jun 03, 2021

In what is a major development for Creso Pharma (ASX: CPH), target acquisition company Halucencex Life Sciences is fast tracking its go to market strategy in California. This follows the recent passing of Senate Bill 519 through the California State Senate, which if signed into law, would make a wide range of psychedelic substances including psilocybin legal to use and possess for adults over the age of 21.

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

Finfeed Archived May 26, 2021

Creso Pharma's target acquisition group Halucenex has entered into an agreement with consultancy group, HetereoGeneity

CPH further derisks acquisition as Halucenex adds to its psychedelics supply

Finfeed Archived May 14, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) target acquisition company Halucenex Life Sciences has nearly doubled its supply of synthetic psilocybin. Halucenex has secured an additional 10 grams of synthetic psilocybin from its manufacturing partner – Canada’s only pharmaceutical grade synthetic psilocybin producer.

Halucenex forms important partnership as psychedelics space heats

Finfeed Archived May 06, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world.

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

Finfeed Archived Apr 30, 2021

There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.

The NASDAQ Listing We Will be Watching Tonight

Next Investors Apr 27, 2021

Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.

Move to legalisation of psychedelics could benefit CPH in the US

Finfeed Archived Apr 19, 2021

Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucencex Life Sciences Inc. has signed a non-binding Letter of Intent (LOI) with leading nanotechnology company Sixth Wave Inc. as California pushes to decriminalise psychedelics, which highlights the ongoing acceptance and regulatory shift towards psychedelics as an alternative treatment route for debilitating mental health conditions.

Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds

Finfeed Archived Apr 12, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) has provided an update regarding target acquisition company, Halucenex Life Sciences, outlining its entry into an advisory agreement with Growing Together Research Inc. (GTR) to explore the genome sequencing of natural psilocybe.

Halucenex agreement to give CPH another leg up in psychedelics

Finfeed Archived Mar 31, 2021

Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.

$18M will help CPH progress near-term revenue initiatives

Finfeed Archived Mar 26, 2021

Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.

CPH to list on the OTC as it expands North American footprint

Finfeed Archived Mar 23, 2021

Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.

$15M grant for psychedelics studies as calls to combat mental health intensify

Finfeed Archived Mar 18, 2021

Australia’s federal government will grant $15M to clinical studies that explore the use of psychedelic drugs like magic mushrooms and ecstasy, to treat Australians with debilitating mental illnesses.

Creso Pharma set to be the first ASX listed entrant in new market

Finfeed Archived Mar 15, 2021

Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed an agreement to acquire Halucenex Life Sciences Inc. (Halucenex), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.

Page 1 of 2 next >